JPMorgan Chase & Co. Increases GSK (LON:GSK) Price Target to GBX 1,660

GSK (LON:GSK) had its price objective boosted by investment analysts at JPMorgan Chase & Co. from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) in a research note issued to investors on Thursday, MarketBeat.com reports. The firm currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential downside of 4.24% from the stock’s current price.

GSK has been the topic of several other research reports. Berenberg Bank boosted their target price on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($24.49) target price on shares of GSK in a report on Wednesday, April 17th. Barclays reaffirmed an “equal weight” rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Monday, April 8th. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, GSK has a consensus rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.05).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,733.50 ($21.77) on Thursday. The company has a quick ratio of 0.73, a current ratio of 0.88 and a debt-to-equity ratio of 140.82. GSK has a twelve month low of GBX 1,302.60 ($16.36) and a twelve month high of GBX 1,739.56 ($21.85). The stock has a market cap of £70.90 billion, a price-to-earnings ratio of 1,444.58, a P/E/G ratio of 1.12 and a beta of 0.27. The company’s fifty day moving average is GBX 1,662.06 and its 200 day moving average is GBX 1,556.29.

Insiders Place Their Bets

In related news, insider Urs Rohner acquired 434 shares of the stock in a transaction dated Wednesday, March 20th. The shares were purchased at an average price of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,060.52). In related news, insider Emma Walmsley sold 139,792 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,382.19). Also, insider Urs Rohner bought 434 shares of GSK stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average cost of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,060.52). Corporate insiders own 1.77% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.